Clinical Focus

• Minimally Invasive (Keyhole) Spine Surgery (for slipped discs, canal stenosis).
• Craniovertebral Junction (CVJ) Anomalies like Atlantoaxial Dislocations/fractures.
• Spinal Fractures – including cementing (Kyphoplasty and Vertebroplasty).
• Endoscopic Spine Surgery (for slipped discs and tumors).
• Spinal Deformity correction (Kyphosis and Scoliosis).
• Spinal Tumors – including keyhole tumor removal.
• Disc replacement (Artificial Disc Placements).
• Spinal Tuberculosis & Discitis.

Awards

• 2010 - Recipient of coveted World Federation of Neurosurgical Societies Travelling Fellowship to the USA.
• 2014 - Recipient of Global Healthcare Excellence Award for Excellence in Spine Surgery.
• 2015 - Recipient of 2015 Leaders Award for Leader in Treatment of Spinal Disorders.
• 2016 - Recipient of National Healthcare Excellence Award for Best Neurosciences team of the year.

Research and Publications

• Clinical research associate in protocol 94CE 32 .Phase III comparative study of combination treatment with TLC D99 liposomal doxorubicin and cyclophosphamide and doxorubicin in metastatic breast cancer.
• A Multicentric, open label phase III clinical trial to evaluate the safety of filgrastim in cancer patients with grade 3 or 4 chemotherapy induced neutropenia.
• Organizing secretary, 4th international seminar on psychosocial oncology, new delhi ,April 1999.  TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First- Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer”.
• SB3-G31-BC: “A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting”.
• A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer or Colorectal cancer under fed condition.
• A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients.
• A multicenter, open label, balanced, randomized, two treatment, three period, three sequence, reference replicate crossover, single dose, oral bioequivalence study of Capecitabine film coated tablets 500mg of Shilpa Medicare Limited, India & Xeloda film coated tablets 500mg (Capecitabine) marketed by Roche Registration limited, 6 Falcon way, Shire park, Welwyn garden city, AL71 TW United Kingdome following single oral dose of 2000mg (4x500mg) in adult human cancer patients under fed conditions.

Memberships

• North American Spine Society, USA.
• Neurological Society of India.
• Association of Spine Surgeons of India.
• Neurological Surgeons Society of India.
• Neuro Spinal Surgeons Association, India.
• Minimally Invasive Spine Surgeons of India.
• World Federation of Neurosurgical Societies, USA.